NPS Intelligence (beta)

Disclosed NPS & retention by vertical

Verticals  /  Pharma, medtech & health distribution  /  Better Therapeutics, Inc.

Better Therapeutics, Inc.

61
Latest disclosed NPS
11 Mar 2024
6
NPS entries
6 with a number
2022–24
Years covered
6 entries in all

In their words

“Improved 61 mood Mean A1C reduction for NPS Score at •”
— Better Therapeutics, Inc. · SEC 8-K filing · filed 11 Mar 2024
“Change in FAST Score of 20% (p=0.01), (iii) no serious adverse events or device related adverse events, and (iv) high engagement and patient satisfaction with treatment, with a Net Promoter Score of +75 and 94% of subjects still using the app after…”
— Better Therapeutics, Inc. · SEC S-1 IPO prospectus · filed 6 Feb 2024
“Change in FAST Score of 20% (p=0.01), (iii) no serious adverse events or device related adverse events, and (iv) high engagement and patient satisfaction with treatment, with a Net Promoter Score of +75 and 94% of subjects still using the app after…”
— Better Therapeutics, Inc. · SEC 10-K annual report · filed 30 Mar 2023

Disclosed NPS over time

Every Net Promoter Score Better Therapeutics, Inc. has published, by date.

6070802023616175757561

NPS disclosures (6)

Search the database →

11 Mar 2024
NPS61

…Improved 61 mood Mean A1C reduction for NPS Score at •

— Better Therapeutics, Inc. · SEC 8-K filing · filed 11 Mar 2024
SEC 8-K filing ↗
6 Feb 2024
NPS75

…change in FAST Score of 20% (p=0.01), (iii) no serious adverse events or device related adverse events, and (iv) high engagement and patient satisfaction with treatment, with a Net Promoter Score of +75 and 94% of subjects still using the app after…

— Better Therapeutics, Inc. · SEC S-1 IPO prospectus · filed 6 Feb 2024
SEC S-1 IPO prospectus ↗
30 Mar 2023
NPS75

…change in FAST Score of 20% (p=0.01), (iii) no serious adverse events or device related adverse events, and (iv) high engagement and patient satisfaction with treatment, with a Net Promoter Score of +75 and 94% of subjects still using the app after…

— Better Therapeutics, Inc. · SEC 10-K annual report · filed 30 Mar 2023
SEC 10-K annual report ↗
12 Dec 2022
NPS75

High engagement and patient satisfaction with treatment, with Net Promoter Score of +75 and 94% of subjects still using the app after 90 days “The results seen in the LivVita Study give us confidence that there is merit in further development of…

— Better Therapeutics, Inc. · SEC 8-K filing · filed 12 Dec 2022
SEC 8-K filing ↗
14 Sep 2022
NPS61

…engagement and persistence exceeded benchmarks for consumer health & wellness apps* 5.9 81% 61 Average minutes / day NPS Score after Percentage of patients spent in app using the app at 180 days 180 days % % % % 36 38 36 35 Healthcare Medical Fitness…

— Better Therapeutics, Inc. · SEC 8-K filing · filed 14 Sep 2022
SEC 8-K filing ↗
28 Jul 2022
NPS61

…exceed benchmarks for consumer health & wellness apps* % 5.9 81 61 Average minutes / day Percentage of patients NPS Score after spent in app using the app at 180 days 180 days % % % % 36 38 36 35 Healthcare Health Medical Fitness (all) Insurance 28…

— Better Therapeutics, Inc. · SEC 8-K filing · filed 28 Jul 2022
SEC 8-K filing ↗

Retention disclosures (0)

Open in the retention database →

No retention figures yet.

Lighthouse companies in Pharma, medtech & health distribution

The whole vertical →

About these figures

Every figure here was publicly disclosed by the named company: press releases, annual reports, SEC filings, earnings calls and news coverage. Companies tend to publish their NPS when it is good, so these numbers run higher than a true industry average: read them as what leading companies in this vertical say publicly, not as an industry benchmark.

NPS runs from −100 to +100. Retention figures are reported as the company defines them (net revenue retention, gross revenue retention, customer retention rate, churn). Every entry links to its source in the full database.